Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
Limentani SA, Campone M, Dorval T, Curigliano G, de Boer R, Vogel C, White S, Bachelot T, Canon JL, Disis M, Awada A, Berlière M, Amant F, Levine E, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. Limentani SA, et al. Among authors: dorval t. Breast Cancer Res Treat. 2016 Apr;156(2):319-30. doi: 10.1007/s10549-016-3751-x. Epub 2016 Mar 18. Breast Cancer Res Treat. 2016. PMID: 26993131 Clinical Trial.
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. Curigliano G, et al. Among authors: dorval t. Breast Cancer Res Treat. 2016 Apr;156(2):301-10. doi: 10.1007/s10549-016-3750-y. Epub 2016 Mar 14. Breast Cancer Res Treat. 2016. PMID: 26975189 Clinical Trial.
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U. Kruit WH, et al. Among authors: dorval t. J Clin Oncol. 2013 Jul 1;31(19):2413-20. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28. J Clin Oncol. 2013. PMID: 23715572 Clinical Trial.
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M. Kruit WH, et al. Among authors: dorval t. Int J Cancer. 2005 Nov 20;117(4):596-604. doi: 10.1002/ijc.21264. Int J Cancer. 2005. PMID: 15945101 Clinical Trial.
The impact of the loco-regional treatment in elderly breast cancer patients: hypo-fractionated exclusive radiotherapy, single institution long-term results.
Chargari C, Kirova YM, Laki F, Savignoni A, Dorval T, Dendale R, Bollet MA, Fourquet A, Campana F; Institut Curie Breast Cancer Study Group. Chargari C, et al. Among authors: dorval t. Breast. 2010 Oct;19(5):413-6. doi: 10.1016/j.breast.2010.04.004. Epub 2010 May 18. Breast. 2010. PMID: 20483616 Free article.
Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, Beuzeboc P, Dorval T, Pouillart P. Fizazi K, et al. Among authors: dorval t. Cancer. 1996 Apr 1;77(7):1315-23. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1315::AID-CNCR14>3.0.CO;2-4. Cancer. 1996. PMID: 8608509 Clinical Trial.
Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
Dorval T, Négrier S, Chevreau C, Avril MF, Baume D, Cupissol D, Oskam R, de Peuter R, Vinke J, Herrera A, Escudier B. Dorval T, et al. Cancer. 1999 Mar 1;85(5):1060-6. doi: 10.1002/(sici)1097-0142(19990301)85:5<1060::aid-cncr8>3.0.co;2-2. Cancer. 1999. PMID: 10091789 Clinical Trial.
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T. van Baren N, et al. Among authors: dorval t. J Clin Oncol. 2005 Dec 10;23(35):9008-21. doi: 10.1200/JCO.2005.08.375. Epub 2005 Aug 1. J Clin Oncol. 2005. PMID: 16061912 Clinical Trial.
Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90).
Pierga JY, Jouve M, Asselain B, Livartowski A, Beuzeboc P, Diéras V, Scholl S, Dorval T, Palangié T, Garcia-Giralt E, Pouillart P. Pierga JY, et al. Among authors: dorval t. Br J Cancer. 1998 May;77(9):1474-9. doi: 10.1038/bjc.1998.242. Br J Cancer. 1998. PMID: 9652764 Free PMC article. Clinical Trial.
147 results